股本结构

单位:万股
公告日期 2021-02-24 2020-11-30 2020-11-16 2020-09-02 2020-08-11 2020-08-11
证券总股本 1810.80 1809.31 1809.30 1809.31 18093.10 11146.50
普通股本 1810.80 1809.31 1809.30 1809.31 18093.10 11146.50
优先股 1.00 未披露 1.00 未披露 未披露 2.00
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2020-12-31 2020-11-27 2020-09-30 2020-09-03 2020-08-06 2020-06-30
注释:中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本(万股) 变动后优先股(万股) 变动原因 变动日期
2021-02-24 3700.00 未披露
更多>>
Immediately following the Effective Time, there were approximately 37.0 million shares of Common Stock outstanding (post Reverse Stock Split). Immediately following the Effective Time, the former Viracta stockholders owned approximately 86.05% of the outstanding shares of Common Stock, and the Company’s stockholders immediately prior to the Merger, whose shares of Common Stock remain outstanding after the Merger, owned approximately 13.95% of the outstanding shares of Common Stock.
2021-02-25
2021-02-24 1810.80 1.00
更多>>
From December 31,2019 to December 31,2020 Issuance of $13,800 of common stock, net of issuance cost of $1,167 Issuance of common stock upon conversion of preferred stock Issuance of common stock under employee stock purchase plans
2020-12-31
2020-11-30 1809.31 未披露 定期报告 2020-11-27
2020-11-16 1809.30 1.00
更多>>
From June 30, 2020 to September 30, 2020 Conversion of preferred stock to common stock Issuance of common and preferred stock in underwritten
2020-09-30
2020-09-02 1809.31 未披露
更多>>
On September 2, 2020, Sunesis Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to Amended and Restated Certificate of Incorporation of Sunesis Pharmaceuticals, Inc. (the “Amendment”) to effect a one-for-ten reverse stock split of its outstanding common stock, effective as of September 2, 2020 (the “Reverse Stock Split”). A series of alternate amendments to effect the Reverse Stock Split was approved by the Company’s stockholders at its Annual Meeting of Stockholders held on June 16, 2020, and the specific one-for-ten ratio was subsequently approved by the Company’s Board of Directors on August 17, 2020.
2020-09-03
2020-08-11 18093.10 未披露 定期报告 2020-08-06
2020-07-31 16356.71 未披露
更多>>
1.Common stock offered by the company 52,173,913 shares. 2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 111,393,236 shares of common stock outstanding as of March 31, 2020.
2020-07-31
2020-08-11 11146.50 2.00
更多>>
From March 31, 2020 to June 30, 2020 Issuance of common stock under employee stock purchase plans
2020-06-30
2020-04-28 11139.32 未披露 定期报告 2020-02-28
2020-03-10 11139.30 2.00
更多>>
From December 31,2018 to December 31,2019 Issuance of $38,000 of common stock, $10,000 preferred stock,net of issuance cost of $3,400 Issuance of common stock upon conversion of preferred stock Issuance of $473 of common stock through controlled equity offering facilities, net of issuance costs of $9 Issuance of common stock from vesting of restricted stock awards Issuance of common stock under employee stock purchase plans
2019-12-31
2019-08-07 11132.00 未披露 定期报告 2019-08-01
2019-07-15 10091.18 未披露 定期报告 2019-07-15
2019-05-08 7252.80 未披露 定期报告 2019-05-01
2019-03-07 6757.81 未披露 定期报告 2019-03-01
2019-03-07 3747.40 1.80
更多>>
from December 31, 2017 to December 31, 2018 Issuance of $6,068 of common stock through controlled equity offering facilities, net of issuance costs of $77 Issuance of common stock from vesting of restricted stock awards Issuance of common stock under employee stock purchase plans Issuance of common stock pursuant to stock option exercises
2018-12-31
2019-01-22 3742.15 1.77 定期报告 2018-09-30
2018-08-08 3613.70 未披露 定期报告 2018-08-02
2018-04-25 3437.12 未披露 定期报告 2018-04-10
2018-03-09 3434.89 未披露 定期报告 2018-03-01
2018-03-09 3429.10 1.77
更多>>
from December 31, 2016 to December 31, 2017 Issuance of $15,000 of common stock, $5,000 of preferred stock, and warrants in underwritten offering, net of issuance costs about $1,500 Issuance of common stock upon conversion of preferred stock Issuance of $14,468 of common stock through controlled equity offering facilities, net of issuance costs of $289 Issuance of common stock under employee stock purchase plans Issuance of common stock pursuant to stock option exercises
2017-12-31
2017-11-02 3424.83 未披露 定期报告 2017-10-27
2017-10-26 2398.87 1.52 定期报告 2017-09-30
2017-07-27 2351.32 未披露 定期报告 2017-07-21
2017-04-20 2146.05 未披露 定期报告 2017-04-04
2017-04-20 2093.69 未披露 定期报告 2017-03-01
2017-03-09 2092.45 未披露 定期报告 2017-02-24
2017-03-09 2092.50 1.79
更多>>
from December 31, 2015 to December 31, 2016 Issuance of common stock upon conversion of preferred stock Issuance of preferred stock Issuance of $21,852 of common stock in underwritten offering, net of issuance costs of $1,497 Issuance of $269 of common stock through controlled equity offering facilities, net of issuance costs of $5 Issuance of common stock under employee stock purchase plans On September 7, 2016, the Company effected a one-for-six reverse split of its common stock (the "Reverse Split"), as previously authorized and approved at the annual meeting of stockholders on June 7, 2016.
2016-12-31
2016-11-03 2087.87 未披露
更多>>
In October 2016, the Company completed underwritten offerings of (i) 5,675,825 shares of its common stock, that included the exercise of the underwriter's over-allotment option of 740,325 shares, at a price to the public of $3.85 per share, and (ii) 1,558 shares of our non-voting Series C Convertible Preferred Stock (“Series C Stock”) at a price to the public of $3,850.00 per share.
2016-10-24
2016-09-07 1450.24 未披露
更多>>
The company to effect a one-for-six reverse stock split of its outstanding common stock, effective as of September 7, 2016.
2016-09-08
2016-07-29 8701.44 未披露 定期报告 2016-07-22
2016-04-25 8693.50 未披露 定期报告 2016-04-11
2016-03-14 8651.78 未披露 定期报告 2016-02-26
2016-03-14 8651.80 2020.00
更多>>
from December 31, 2014 to December 31, 2015 Issuance of preferred stock Issuance of $9,236 of common stock in underwritten offering, net of issuance costs of $527 Issuance of $18,564 of common stock through controlled equity offering facilities, net of issuance costs of $439 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
2015-12-31
2015-07-30 7547.09 未披露 定期报告 2015-07-30
2015-05-05 7296.03 未披露 定期报告 2015-04-30
2015-04-28 7061.74 未披露 定期报告 2015-04-10
2015-03-12 6773.98 未披露 定期报告 2015-02-27
2015-03-12 6610.20 未披露
更多>>
From December 31,2013 to December 31,2014 Issuance of $43,013 of common stock and warrants in underwritten offering, net of issuance costs of $2,989 Issuance of $14,734 of common stock through controlled equity offering facilities, net of issuance costs of $442 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
2014-12-31
2014-11-10 6194.91 未披露 定期报告 2014-10-31
2014-08-05 6044.30 未披露 定期报告 2014-07-25
2014-05-07 6021.70 未披露 定期报告 2014-04-30
2014-05-07 6016.27 未披露 定期报告 2014-03-31
2014-03-06 6009.48 未披露 定期报告 2014-03-04
2014-03-06 5434.40 未披露
更多>>
from December 31, 2012 to December 31, 2013 Issuance of $12,357 of common stock through controlled equity offering facilities, net of issuance costs of $371 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
2013-12-31
2013-11-12 5398.25 未披露 定期报告 2013-10-31
2013-08-02 5169.43 未披露 定期报告 2013-07-31
2013-04-25 5160.91 未披露 定期报告 2013-04-09
2013-03-13 5158.38 未披露 定期报告 2013-02-28
2013-03-13 5156.50 未披露
更多>>
from December 31, 2011 to December 31, 2012 Issuance of $18,124 of common stock through controlled equity offering facilities, net of issuance costs of $504 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
2012-12-31
2012-11-08 5150.03 未披露 定期报告 2012-10-31
2012-08-09 4710.50 未披露 定期报告 2012-07-31
2012-05-15 4692.42 未披露 定期报告 2012-04-30
2012-03-14 4682.01 未披露 定期报告 2012-03-01
2012-03-14 4677.40 未披露
更多>>
from December 31, 2010 to December 31, 2011 Issuance of $4,178 of common stock through controlled equity offering facilities, net of issuance costs of $125 Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
2011-12-31
2011-08-11 4671.37 未披露 定期报告 2011-07-31
2011-03-29 4602.75 未披露 定期报告 2011-03-15
2011-03-29 4537.17 未披露
更多>>
from dec 31 2009 to dec 31 2010 Issuance of common stock upon conversion of preferred stock Issuance of $28,500,000 of common stock in third closing of Private Placement, net of issuance costs of $1,786,786 Issuance of $28,819,974 of common stock through controlled equity offering facilities, net of issuance costs of $1,332,292 Issuance of $10,961,379 of common stock in 2010 Offering, net of issuance costs of $1,233,056 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plan Issuance of common stock to employees
2010-12-31
2010-11-04 26606.48 未披露 定期报告 2010-10-15
2010-08-13 22182.16 未披露 定期报告 2010-07-31
2010-04-29 5798.12 未披露 定期报告 2010-04-15
2005-09-27 2145.58 未披露 定期报告 2005-09-27
Immediately following the Effective Time, there were approximately 37.0 million shares of Common Stock outstanding (post Reverse Stock Split). Immediately following the Effective Time, the former Viracta stockholders owned approximately 86.05% of the outstanding shares of Common Stock, and the Company’s stockholders immediately prior to the Merger, whose shares of Common Stock remain outstanding after the Merger, owned approximately 13.95% of the outstanding shares of Common Stock.
From December 31,2019 to December 31,2020 Issuance of $13,800 of common stock, net of issuance cost of $1,167 Issuance of common stock upon conversion of preferred stock Issuance of common stock under employee stock purchase plans
From June 30, 2020 to September 30, 2020 Conversion of preferred stock to common stock Issuance of common and preferred stock in underwritten
On September 2, 2020, Sunesis Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to Amended and Restated Certificate of Incorporation of Sunesis Pharmaceuticals, Inc. (the “Amendment”) to effect a one-for-ten reverse stock split of its outstanding common stock, effective as of September 2, 2020 (the “Reverse Stock Split”). A series of alternate amendments to effect the Reverse Stock Split was approved by the Company’s stockholders at its Annual Meeting of Stockholders held on June 16, 2020, and the specific one-for-ten ratio was subsequently approved by the Company’s Board of Directors on August 17, 2020.
1.Common stock offered by the company 52,173,913 shares. 2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 111,393,236 shares of common stock outstanding as of March 31, 2020.
From March 31, 2020 to June 30, 2020 Issuance of common stock under employee stock purchase plans
From December 31,2018 to December 31,2019 Issuance of $38,000 of common stock, $10,000 preferred stock,net of issuance cost of $3,400 Issuance of common stock upon conversion of preferred stock Issuance of $473 of common stock through controlled equity offering facilities, net of issuance costs of $9 Issuance of common stock from vesting of restricted stock awards Issuance of common stock under employee stock purchase plans
from December 31, 2017 to December 31, 2018 Issuance of $6,068 of common stock through controlled equity offering facilities, net of issuance costs of $77 Issuance of common stock from vesting of restricted stock awards Issuance of common stock under employee stock purchase plans Issuance of common stock pursuant to stock option exercises
from December 31, 2016 to December 31, 2017 Issuance of $15,000 of common stock, $5,000 of preferred stock, and warrants in underwritten offering, net of issuance costs about $1,500 Issuance of common stock upon conversion of preferred stock Issuance of $14,468 of common stock through controlled equity offering facilities, net of issuance costs of $289 Issuance of common stock under employee stock purchase plans Issuance of common stock pursuant to stock option exercises
from December 31, 2015 to December 31, 2016 Issuance of common stock upon conversion of preferred stock Issuance of preferred stock Issuance of $21,852 of common stock in underwritten offering, net of issuance costs of $1,497 Issuance of $269 of common stock through controlled equity offering facilities, net of issuance costs of $5 Issuance of common stock under employee stock purchase plans On September 7, 2016, the Company effected a one-for-six reverse split of its common stock (the "Reverse Split"), as previously authorized and approved at the annual meeting of stockholders on June 7, 2016.
In October 2016, the Company completed underwritten offerings of (i) 5,675,825 shares of its common stock, that included the exercise of the underwriter's over-allotment option of 740,325 shares, at a price to the public of $3.85 per share, and (ii) 1,558 shares of our non-voting Series C Convertible Preferred Stock (“Series C Stock”) at a price to the public of $3,850.00 per share.
The company to effect a one-for-six reverse stock split of its outstanding common stock, effective as of September 7, 2016.
from December 31, 2014 to December 31, 2015 Issuance of preferred stock Issuance of $9,236 of common stock in underwritten offering, net of issuance costs of $527 Issuance of $18,564 of common stock through controlled equity offering facilities, net of issuance costs of $439 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
From December 31,2013 to December 31,2014 Issuance of $43,013 of common stock and warrants in underwritten offering, net of issuance costs of $2,989 Issuance of $14,734 of common stock through controlled equity offering facilities, net of issuance costs of $442 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
from December 31, 2012 to December 31, 2013 Issuance of $12,357 of common stock through controlled equity offering facilities, net of issuance costs of $371 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
from December 31, 2011 to December 31, 2012 Issuance of $18,124 of common stock through controlled equity offering facilities, net of issuance costs of $504 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
from December 31, 2010 to December 31, 2011 Issuance of $4,178 of common stock through controlled equity offering facilities, net of issuance costs of $125 Issuance of common stock under employee stock purchase plans Issuance of common stock to employees
from dec 31 2009 to dec 31 2010 Issuance of common stock upon conversion of preferred stock Issuance of $28,500,000 of common stock in third closing of Private Placement, net of issuance costs of $1,786,786 Issuance of $28,819,974 of common stock through controlled equity offering facilities, net of issuance costs of $1,332,292 Issuance of $10,961,379 of common stock in 2010 Offering, net of issuance costs of $1,233,056 Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to stock option exercises Issuance of common stock under employee stock purchase plan Issuance of common stock to employees